Vascular endothelial growth factor biology: clinical implications for ocular treatments

被引:136
作者
Bhisitkul, R. B. [1 ]
机构
[1] Univ Calif San Francisco, Beckman Vis Ctr, Dept Ophthalmol, San Francisco, CA 94143 USA
关键词
D O I
10.1136/bjo.2006.098426
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Decades of research on vascular endothelial growth factor (VEGF) have reached fruition with the recent development of intravitreal anti-VEGF treatments for exudative age-related macular degeneration. VEGF is a critical regulator of angiogenesis and vascular permeability with diverse roles, both pathological and physiological, during development and adulthood. The aim of this article is to review aspects of VEGF biology that may be relevant to the clinical use of anti-VEGF agents in ophthalmology: molecular characteristics and isoforms of VEGF; its roles in vasculogenesis, vascular maintenance and angiogenesis; systemic effects of VEGF inhibition; and properties of current anti-VEGF agents.
引用
收藏
页码:1542 / 1547
页数:6
相关论文
共 74 条
[41]   VASCULAR ENDOTHELIAL GROWTH-FACTOR IS A SECRETED ANGIOGENIC MITOGEN [J].
LEUNG, DW ;
CACHIANES, G ;
KUANG, WJ ;
GOEDDEL, DV ;
FERRARA, N .
SCIENCE, 1989, 246 (4935) :1306-1309
[42]   Intravitreal injection of specific receptor tyrosine kinase inhibitor PTK787/ZK222 584 improves ischemia-induced retinopathy in mice [J].
Maier, P ;
Unsoeld, AS ;
Junker, B ;
Martin, G ;
Drevs, J ;
Hansen, LL ;
Agostini, HT .
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2005, 243 (06) :593-600
[43]   Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function [J].
Marneros, AG ;
Fan, J ;
Yokoyama, Y ;
Gerber, HP ;
Ferrara, N ;
Crouch, RK ;
Olsen, BR .
AMERICAN JOURNAL OF PATHOLOGY, 2005, 167 (05) :1451-1459
[44]   Pathogenesis of persistent hyperplastic primary vitreous in mice lacking the Arf tumor suppressor gene [J].
Martin, AC ;
Thornton, JD ;
Liu, JW ;
Wang, XF ;
Zuo, J ;
Jablonski, MM ;
Chaum, E ;
Zindy, F ;
Skapek, SX .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2004, 45 (10) :3387-3396
[45]  
McColm J, 2004, MOL VIS, V10, P512
[46]  
Meeson AP, 1999, DEVELOPMENT, V126, P1407
[47]   Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration - Twelve-week results of an uncontrolled open-label clinical study [J].
Michels, S ;
Rosenfeld, PJ ;
Puliafito, CA ;
Marcus, EN ;
Venkatraman, AS .
OPHTHALMOLOGY, 2005, 112 (06) :1035-1047
[48]   Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer [J].
Miller, KD ;
Chap, LI ;
Holmes, FA ;
Cobleigh, MA ;
Marcom, PK ;
Fehrenbacher, L ;
Dickler, M ;
Overmoyer, BA ;
Reimann, JD ;
Sing, AP ;
Langmuir, V ;
Rugo, HS .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (04) :792-799
[49]   Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1) [J].
Miyamoto, K ;
Khosrof, S ;
Bursell, SE ;
Moromizato, Y ;
Aiello, LP ;
Ogura, Y ;
Adamis, AP .
AMERICAN JOURNAL OF PATHOLOGY, 2000, 156 (05) :1733-1739
[50]  
Murata T, 1996, LAB INVEST, V74, P68